NCT01951157View on ClinicalTrials.gov

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

September 11, 2013

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Docetaxel

Powder for solution for infusion

DRUG

Gemcitabine

Powder for solution for infusion

DRUG

Lurbinectedin (PM01183)

Powder for concentrate for solution for infusion

Trial Locations (1)

Unknown

New York

Sponsors

Lead Sponsor

PharmaMar
All Listed Sponsors
lead

PharmaMar

INDUSTRY

NCT01951157 - A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients | Biotech Hunter | Biotech Hunter